var data={"title":"Sulfacetamide (topical): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sulfacetamide (topical): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390433?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sulfacetamide-topical-drug-information\" class=\"drug drug_general\">see &quot;Sulfacetamide (topical): Drug information&quot;</a> and <a href=\"topic.htm?path=sulfacetamide-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sulfacetamide (topical): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523091\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>APOP [DSC];</li>\n      <li>Klaron;</li>\n      <li>Ovace Plus;</li>\n      <li>Ovace Plus Wash;</li>\n      <li>Ovace Wash;</li>\n      <li>Seb-Prev Wash;</li>\n      <li>Seb-Prev [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523092\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sulfacet-R</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527093\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Acne Products</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Sulfonamide Derivative</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Topical Skin Product</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527103\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sulfacetamide-topical-drug-information\" class=\"drug drug_general\">see &quot;Sulfacetamide (topical): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acne:</b> Children &ge;12 years and Adolescents: Topical:  Lotion 10%: Apply thin film to affected area twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seborrheic dermatitis, including seborrhea sicca:</b> Children &ge;12 years and Adolescents: Topical: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream, Lotion 9.8%: Apply to affected areas twice daily for 8 to 10 days. Dosing interval may be lengthened as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to be reinitiated, start therapy as a twice daily regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foam: Apply to affected areas 1 to 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gel, Wash: Wash affected area twice with a 10- to 20-second interval between washings; repeat application twice daily for 8 to 10 days. Dosing interval may be lengthened as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to be reinitiated, start therapy as a twice daily regimen. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Shampoo: Wash hair at least twice weekly </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial infections (secondary), cutaneous:</b> Children &ge;12 years and Adolescents: Topical: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream, Lotion 9.8%: Apply to affected areas twice daily for 8 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foam: Apply to affected areas 1 to 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gel: Wash affected area once daily for 8 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Wash: Wash affected area once or twice daily for 8 to 10 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acne:</b> Topical: Lotion 10%, topical suspension: Apply thin film to affected area twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial infections:</b> Topical: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream, Lotion 9.8%: Apply to affected areas twice daily for 8 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foam: Apply to affected areas 1 to 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Wash: Apply to affected areas 1 to 2 times daily for 8 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Scaling dermatoses:</b> Topical: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream, Lotion 9.8%: Apply to affected areas twice daily for 8 to 10 days. Dosing interval may be lengthened as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to be reinitiated, start therapy as a twice-daily regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foam: Apply to affected areas 1 to 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Shampoo: Wash hair at least twice weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Wash:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Ovace Plus Wash Liquid, Ovace Plus Wash cleansing gel, Ovace wash: Wash affected areas twice with a 10- to 20-second interval between washings; repeat twice daily for 8 to 10 days. Dosing interval may be lengthened as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to be reinitiated, start therapy as a twice-daily regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">SEB-Prev: Wash affected areas twice daily for 8 to 10 days. Dosing interval may be lengthened as eruption subsides. Applications once or twice weekly, or every other week may be used for prevention. If treatment needs to be reinitiated, start therapy as a twice-daily regimen.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523207\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ovace Plus: 10% (57 g) [contains benzyl alcohol, butylparaben, cetyl alcohol, disodium edta, ethylparaben, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Foam, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ovace Plus: 9.8% (100 g) [contains benzyl alcohol, cetyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">APOP: 10% (57 g [DSC]) [contains benzyl alcohol, cetyl alcohol, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ovace Plus Wash: 10% (355 mL) [contains benzyl alcohol, cetearyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (355 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, External, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ovace Plus Wash: 10% (180 mL, 473 mL) [contains cetearyl alcohol, edetate disodium, methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ovace Wash: 10% (180 mL, 355 mL, 480 mL [DSC]) [contains edetate disodium, methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Seb-Prev Wash: 10% (340 mL) [contains edetate disodium, methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (177 mL, 180 mL, 354.8 mL, 355 mL, 480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Klaron: 10% (118 mL) [contains disodium edta, methylparaben, propylene glycol, sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ovace Plus: 9.8% (57 g, 113 g) [contains benzyl alcohol, cetyl alcohol, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Seb-Prev: 10% (118 mL [DSC]) [contains methylparaben, sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (118 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Shampoo, External, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ovace Plus: 10% (237 mL) [contains cetearyl alcohol, methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (237 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, External, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% (118 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523094\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25827573\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=sulfacetamide-topical-drug-information\" class=\"drug drug_general\">see &quot;Sulfacetamide (topical): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">APOP gel is formulated in a vehicle containing 0.5% bakuchiol, a natural compound extracted from<i> Psoralea corylifolia</i>  purported to exert antimicrobial and anti-inflammatory activity, as well as reduce scarring from acne lesions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527184\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For external use only; avoid contact with eyes and mucous membranes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foam: Cleanse affected skin thoroughly and pat dry before each application. Shake well prior to use. Dispense into palm of hand. Massage into affected areas and wait 10 minutes; rinse thoroughly with water and pat dry.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lotion: Shake lotion well prior to use; apply a thin film to affected area.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Shampoo: Shake shampoo well prior to use. Apply to wet hair and massage vigorously into scalp; thoroughly rinse hair. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, Wash: Apply to wet hair or skin and massage into a full lather; rinse thoroughly and pat dry; repeat after 10 to 20 seconds (for seborrheic dermatitis). If skin dryness occurs, rinse off early or use less frequently. Regular shampooing after use on hair is not necessary; however, hair should be shampooed at least once weekly. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523146\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, shampoo, Ovace Plus lotion: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from freezing and excess heat. May darken slightly on storage; efficacy or safety is not affected. Keep tightly closed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foam: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Brief exposures to temperatures up to 40&deg;C (104&deg;F) may be tolerated provided the mean temperature does not exceed 25&deg;C (77&deg;F); however, such exposure should be minimized. Contents under pressure, do not puncture or incinerate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Klaron lotion, topical suspension: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Keep tightly closed.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Wash: May darken slightly on storage; efficacy or safety is not affected. Keep tightly closed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ovace Plus Wash cleansing gel: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from freezing and excess heat.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ovace Wash, Ovace Plus Wash liquid: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Brief exposures to temperatures up to 40&deg;C (104&deg;F) may be tolerated provided the mean temperature does not exceed 25&deg;C (77&deg;F); however, such exposure should be minimized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SEB-Prev: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from freezing and excess heat.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527094\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lotion (10%): Topical treatment of acne vulgaris (FDA approved in &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, Cream, Foam, Lotion (9.8%), Wash: Topical treatment of scaling dermatoses (including seborrheic dermatitis, seborrhea sicca); secondary cutaneous bacterial infections due to organisms susceptible to sulfonamides (FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Shampoo: Topical treatment of scaling dermatoses (including seborrheic dermatitis, seborrhea sicca) (FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Approved ages and uses for generic products may vary; consult labeling for specific information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523082\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Klaron may be confused with Klor-Con</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523139\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Burning sensation of skin, erythema, pruritus, Stevens-Johnson syndrome, stinging of the skin, toxic epidermal necrolysis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, hematologic abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Fulminant hepatic necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation, localized edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Systemic lupus erythematosus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523126\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known or suspected hypersensitivity to sulfonamides or any component of the formulation; kidney disease (Ovace Plus Wash, Ovace Plus lotion, Ovace Plus foam)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Note:</b> Although the FDA approved product labeling states this medication is contraindicated with other sulfonamide-containing drug classes, the scientific basis of this statement has been challenged. See &ldquo;Warnings/Precautions&rdquo; for more detail.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523127\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Autoimmune effects: Fatalities associated with severe reactions, including drug-induced systemic lupus erythematosus, have occurred with sulfonamides (regardless of administration route).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood dyscrasias: Fatalities associated with severe reactions, including agranulocytosis, acute hemolytic anemia, aplastic anemia, purpura hemorrhagica, and other blood dyscrasias, have occurred with sulfonamides (regardless of route).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermatologic reactions: Fatalities associated with severe reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug fever, have occurred with sulfonamides (regardless of route). In addition, contact dermatitis, reddening, and scaling of the skin may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Fatalities associated with severe reactions, including fulminant hepatic necrosis and jaundice, have occurred with sulfonamides (regardless of route).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions:  Skin rash or other reactions have occurred in patients with no prior history of sulfonamide hypersensitivity.  Discontinue use at the first sign of hypersensitivity or rash.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfonamide (&ldquo;sulfa&rdquo;) allergy: Traditionally, concerns for cross-reactivity have extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur, or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides. A nonantibiotic sulfonamide compound which contains the arylamine structure and therefore may cross-react with antibiotic sulfonamides is sulfasalazine (Zawodniak 2010). T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Systemic effects: Systemic absorption is increased with application to large, infected, abraded, denuded, or burned skin. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: For external use only; not for ophthalmic use; avoid contact with eyes and mucous membranes. Discontinue use if irritation, rash, or signs of hypersensitivity occur. Monitor closely for local irritation and/or sensitization during long-term therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infection: Application to infected area containing nonsusceptible organisms may cause proliferation of the organism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Metabisulfites: Some products contain sodium metabisulfite which may cause allergic reactions in certain individuals (eg, asthmatic patients). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Other topical products: Not compatible with silver-containing products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535384\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300090\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523141\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16048&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523101\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523102\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. The amount of sulfacetamide available systemically following topical administration is unknown. Use of systemic sulfonamides during pregnancy may cause kernicterus in the newborn.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10527185\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Response to therapy; signs of local irritation and/or sensitization, especially during long-term therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523159\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523161\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Significant absorption through skin has been reported; percutaneous absorption about 4%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Sulfanilamide (major metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 7 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine 0.08% to 0.33%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9523209\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Ovace Plus External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (57 g): $562.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Foam</b> (Ovace Plus External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9.8% (100 g): $582.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Ovace Plus Wash External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (355 mL): $745.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Sulfacetamide Sodium External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (cleansing gel) (355 mL): $500.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Ovace Plus Wash External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (180 mL): $246.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Ovace Wash External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (180 mL): $384.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Seb-Prev Wash External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (340 mL): $158.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Sulfacetamide Sodium External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (354.8 mL): $148.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Klaron External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (118 mL): $353.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Ovace Plus External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9.8% (57 g): $611.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Sulfacetamide Sodium (Acne) External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (118 mL): $188.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Shampoo</b> (Ovace Plus External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (237 mL): $636.36</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/15303450/pubmed\" target=\"_blank\" id=\"15303450\">15303450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.  <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/15644481/pubmed\" target=\"_blank\" id=\"15644481\">15644481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaron lotion (sulfacetamide topical) [prescribing information]. Bridgewater, NJ: Dermik Laboratories; July 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ovace Plus cream (sulfacetamide topical) [prescribing information]. San Antonio, TX: Mission Pharmacol Company; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ovace Plus foam (sulfacetamide topical) [prescribing information]. San Antonio, TX: Mission Pharmacol Company; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ovace Plus lotion (sulfacetamide topical) [prescribing information]. San Antonio, TX: Mission Pharmacol Company; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ovace Plus shampoo (sulfacetamide topical) [prescribing information]. San Antonio, TX: Mission Pharmacol Company; December 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ovace Plus wash (sulfacetamide topical) [prescribing information]. San Antonio, TX: Mission Pharmacol Company; Jult 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    SEB-Prev Wash (sulfacetamide topical) [prescribing information]. Minneapolis, MN: Perrigo; February 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/15242722/pubmed\" target=\"_blank\" id=\"15242722\">15242722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sodium sulfacetamide 10% cleansing gel (sulfacetamide topical) [prescribing information]. Alpharetta, GA: Acella Pharmaceuticals, LLC; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sodium sulfacetamide 10% lotion (sulfacetamide topical) [prescribing information]. Bridgewater, NJ: Oceanside Pharmaceuticals; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sodium sulfacetamide 10% shampoo (sulfacetamide topical) [prescribing information]. San Antonio, TX: Biocomp Pharma, Inc; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/15373844/pubmed\" target=\"_blank\" id=\"15373844\">15373844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. <i>Int Arch Allergy Immunol</i>. 2010;153(2):152-156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfacetamide-topical-pediatric-drug-information/abstract-text/20413982/pubmed\" target=\"_blank\" id=\"20413982\">20413982</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16048 Version 109.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9523091\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9523092\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10527093\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10527103\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9523207\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9523094\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25827573\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10527184\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9523146\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10527094\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9523082\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9523139\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9523126\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9523127\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535384\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300090\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9523141\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9523101\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9523102\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10527185\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9523159\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9523161\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9523209\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16048|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sulfacetamide-topical-drug-information\" class=\"drug drug_general\">Sulfacetamide (topical): Drug information</a></li><li><a href=\"topic.htm?path=sulfacetamide-topical-patient-drug-information\" class=\"drug drug_patient\">Sulfacetamide (topical): Patient drug information</a></li></ul></div></div>","javascript":null}